Conference Coverage
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:00:00
- Mas informaciones
Informações:
Sinopsis
Host: Marlene Mimi Maeusli, PhD. A recent Danish population-based study evaluating real-world outcomes of ibrutinib in relapsed or refractory mantle cell lymphoma (MCL) found lower efficacy and tolerability compared to clinical trials, particularly among older patients and those with high-risk disease features. In this AudioAbstract, ReachMD's Dr. Mimi Maeusli explains how this evidence is reshaping our view of ibrutinib's clinical utility.
